Inferring selection in the Anopheles gambiae species complex: an example from immune-related serine protease inhibitors

被引:22
|
作者
Obbard, Darren J. [1 ]
Welch, John J. [1 ]
Little, Tom J. [1 ]
机构
[1] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland
来源
MALARIA JOURNAL | 2009年 / 8卷
基金
英国惠康基金; 英国生物技术与生命科学研究理事会;
关键词
GENETIC DIFFERENTIATION; DROSOPHILA-MELANOGASTER; MOLECULAR EVOLUTION; POSITIVE SELECTION; MALARIA VECTORS; HAPLOTYPE RECONSTRUCTION; NUCLEOTIDE VARIABILITY; POPULATION-GENETICS; ADAPTIVE EVOLUTION; STATISTICAL-METHOD;
D O I
10.1186/1475-2875-8-117
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Mosquitoes of the Anopheles gambiae species complex are the primary vectors of human malaria in sub-Saharan Africa. Many host genes have been shown to affect Plasmodium development in the mosquito, and so are expected to engage in an evolutionary arms race with the pathogen. However, there is little conclusive evidence that any of these mosquito genes evolve rapidly, or show other signatures of adaptive evolution. Methods: Three serine protease inhibitors have previously been identified as candidate immune system genes mediating mosquito-Plasmodium interaction, and serine protease inhibitors have been identified as hot-spots of adaptive evolution in other taxa. Population-genetic tests for selection, including a recent multi-gene extension of the McDonald-Kreitman test, were applied to 16 serine protease inhibitors and 16 other genes sampled from the An. gambiae species complex in both East and West Africa. Results: Serine protease inhibitors were found to show a marginally significant trend towards higher levels of amino acid diversity than other genes, and display extensive genetic structuring associated with the 2La chromosomal inversion. However, although serpins are candidate targets for strong parasite-mediated selection, no evidence was found for rapid adaptive evolution in these genes. Conclusion: It is well known that phylogenetic and population history in the An. gambiae complex can present special problems for the application of standard population-genetic tests for selection, and this may explain the failure of this study to detect selection acting on serine protease inhibitors. The pitfalls of uncritically applying these tests in this species complex are highlighted, and the future prospects for detecting selection acting on the An. gambiae genome are discussed.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC
    Sung, M.
    Zer, A.
    Walia, P.
    Khoja, L.
    Maganti, M.
    Labbe, C.
    Shepherd, F.
    Bradbury, P.
    Liu, G.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S929 - S929
  • [42] Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
    Magahis, Patrick Tiongco
    Corso, Tara
    Livingstone, Pamela
    Tom, Erika
    Srivastava, Amitabh
    Postow, Michael
    Faleck, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07)
  • [43] OPEN-CAPSULE BUDESONIDE FOR THE TREATMENT OF IMMUNE-RELATED ENTERITIS FROM CHECKPOINT INHIBITORS
    Magahis, Patrick T.
    Corso, Tara
    Livingstone, Pamela
    Tom, Erika
    Srivastava, Amitabh
    Postow, Michael
    Faleck, David M.
    GASTROENTEROLOGY, 2024, 166 (05) : S1465 - S1466
  • [44] Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
    Riveiro-Barciela, Mar
    Barreira-Diaz, Ana
    Callejo-Perez, Ana
    Munoz-Couselo, Eva
    Diaz-Mejia, Nely
    Diaz-Gonzalez, Alvaro
    Londono, Maria-Carlota
    Salcedo, Maria-Teresa
    Buti, Maria
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (03) : 732 - 740
  • [45] Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
    Hiroki Nagai
    Manabu Muto
    International Journal of Clinical Oncology, 2018, 23 : 410 - 420
  • [46] Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
    Nagai, Hiroki
    Muto, Manabu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 410 - 420
  • [47] Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
    Riveiro-Barciela, Mar
    Felip, Enriqueta
    Suarez-Almazor, Maria E.
    FRONTIERS IN MEDICINE, 2023, 9
  • [48] Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
    Silverstein, Jordyn
    Wright, Francis
    Wang, Michelle
    Young, Arabella
    Kim, Daniel
    De Dios, Kimberly
    Brondfield, Sam
    Quandt, Zoe
    ONCOLOGIST, 2023, 28 (10): : e950 - e959
  • [49] Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors A Systematic Literature Review
    Ghosh, Nilasha
    Chan, Karmela K.
    Jivanelli, Bridget
    Bass, Anne R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (02) : E498 - E505
  • [50] CHETOTAXIC PROPERTIES OF INTER-LARVAL (STAGE 4) DIFFERENCES BETWEEN SPECIES A AND B OF ANOPHELES GAMBIAE COMPLEX FROM MADAGASCAR
    CHAUVET, G
    DEJARDIN, J
    BIOMETRICS, 1968, 24 (02) : 450 - &